DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–N–2031]

Quality Management Maturity for Finished Dosage Forms Pilot Program for Domestic Drug Product Manufacturers; Program Announcement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency), Center for Drug Evaluation and Research (CDER) is announcing its Quality Management Maturity for Finished Dosage Forms Pilot Program (QMM FDF Pilot Program) for domestic drug product manufacturers of prescription and over-the-counter (OTC) drug products. The purpose of the QMM FDF Pilot Program is to gain insight from third-party assessments of a manufacturer’s quality management system to inform future development of an FDA rating system to characterize quality management maturity (QMM). Such a rating system would allow a cross-sectional comparison of manufacturers. Manufacturers that choose to disclose their facility ratings could benefit from a competitive advantage, as knowledge of QMM ratings would enable health systems and other purchasers and payers of medications to differentiate among drug manufacturers. This notice invites manufacturers that are interested in participating in the QMM FDF Pilot Program to submit a request to participate.

DATES: FDA will accept requests to participate in the QMM FDF Pilot Program through November 30, 2020, and the QMM FDF Pilot Program will run through December 31, 2021. See the “Participation” section for selection criteria and instructions on how to submit a request to participate.

FOR FURTHER INFORMATION CONTACT: For general questions about the QMM FDF Pilot Program: Jennifer Maguire, Center for Drug Evaluation and Research (CDER), 10903 New Hampshire Ave., Silver Spring, MD 20993, Bldg. 51, Rm. 4220, 301–796–1673, Jennifer.Maguire@fda.hhs.gov. To submit a request to participate in the QMM FDF Pilot Program: Seongjin (Cindy) Pak, CDER, Bldg. 51, Rm. 4220, 301–796–1673, Seongjin.Pak@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background


One objective, among others, was to facilitate the implementation of a modern, risk-based pharmaceutical quality assessment system. The desired state has been described as a maximally efficient, agile, flexible pharmaceutical manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

There has been significant progress toward this vision as evidenced by FDA programs and initiatives in such areas as pharmaceutical development and quality by design, quality risk management and pharmaceutical quality systems, process validation, and continual improvement. These programs and initiatives promote use of the best pharmaceutical science and engineering principles throughout the product life cycle.

Another example is the FDA Quality Metrics Program, described in the November 2016 revised draft guidance for industry “Submission of Quality Metrics Data” (81 FR 85226). When final, this guidance will represent FDA’s current thinking on this issue. In June 2018, FDA initiated two voluntary programs that sought additional industry input on quality metrics. FDA solicited industry participation for a Site Visit Program (83 FR 30751) for manufacturing establishments to present the advantages and challenges associated with implementing and managing a quality metrics program, and for a Quality Metrics Feedback Program (83 FR 30748) to engage stakeholders in identifying mutually useful and objective quality metrics.

The Agency continues to develop the FDA Quality Metrics Program but recognizes that quality metrics are only one element within a manufacturer’s larger effort to increase the maturity of their quality management system. Manufacturers that demonstrate QMM operate under an enhanced quality management system that exceeds the minimum standards specified in current good manufacturing practice regulations and focuses on continual improvement. Characteristics of a mature quality management system include, for example, the ability to consistently and reliably deliver quality product over time, operational stability, and a strong quality culture. Additionally, for manufacturers with a mature quality management system, FDA can exercise a more flexible regulatory approach, leading toward the goal of producing high-quality drug products without extensive regulatory oversight.

A transparent method of evaluating and communicating QMM is needed to fully realize the 21st century pharmaceutical quality vision. Toward that end, FDA is announcing the start of the QMM FDF Pilot Program. Through this pilot program, a third-party contractor identified by FDA will conduct an assessment of a manufacturer’s quality management system, accompanied by FDA staff. The Agency will gain insight from the results of the QMM assessments to inform the development of a rating system to measure and rate QMM. Assessments under the QMM FDF Pilot Program will cover multiple topics. Examples include but are not limited to:

1. Supply chain management;
2. manufacturing strategy and operations;
3. safety, environmental, and regulatory compliance;
4. inventory management;
5. performance management and continual improvement;
6. risk management;
7. management review and responsibility;
8. planning;
9. workforce management;
10. quality culture; and
11. customer experience.

In the same timeframe as the QMM FDF Pilot Program, FDA will conduct a QMM pilot program for foreign manufacturers of active pharmaceutical ingredients (APIs), including facilities manufacturing drug substance intermediates used to produce APIs. These pilot programs are funded separately and are intended to provide FDA with representative information about QMM from different types of drug manufacturers (API and FDF).

Elsewhere in this issue of the Federal Register, FDA is publishing “Quality Management Maturity for Active Pharmaceutical Ingredients Pilot Program for Foreign Facilities; Program Announcement.”
II. Participation

Drug product manufacturers located in the United States that are interested in participating in the QMM FDF Pilot Program should submit a written request directly to Seongjin (Cindy) Pak (see FOR FURTHER INFORMATION CONTACT). Participation in the QMM FDF Pilot Program is voluntary. Participants in the Quality Metrics Feedback Program were encouraged to participate in the QMM FDF Pilot Program. FDA will select up to nine participants for the QMM FDF Pilot Program. Participation in the QMM FDF Pilot Program is limited to domestic manufacturing facilities since FDA’s funding source for this program is specific to activities related to domestic manufacturing.

A. Selection Criteria

To be considered for the QMM FDF Pilot Program, participants must meet the following selection criteria:

1. Participant is a U.S.-based manufacturing facility of prescription and/or OTC drug products.
2. All FDA inspection(s) of the manufacturing facility conducted within the 5 years prior to October 1, 2020, received a final classification of “No Action Indicated” or “Voluntary Action Indicated.”
3. Participant agrees to:
   a. Permit a third-party contractor to conduct a QMM assessment, whether the assessment is conducted on-site or remotely. FDA will identify an external contractor having the expertise to assess QMM, and FDA staff will join the contractor for the assessment.
   b. Collect and submit metrics data to FDA and the contractor by an agreed upon date, prior to the assessment. As part of the scope of the discussions for the assessment, FDA will provide the manufacturer with templates and additional details about the data collection.
   c. Be available for consultations with the contractor and FDA prior to and after the assessment, including discussions regarding the participant’s established QMM-related activities and the contractor’s post-assessment recommendations regarding these activities.

During this QMM FDF Pilot Program, the contractor and FDA staff will be available to answer questions and address concerns that arise.

B. Information To Include in the Request

When submitting a request to participate in the QMM FDF Pilot Program, include the information below to aid in FDA’s selection and planning.

- A contact person (name and email);
- Manufacturing facility location;
- Facility FDA Establishment Identifier and Data Universal Numbering System numbers;
- A brief description of the manufacturing operations conducted at the facility;
- Preferred dates for the assessment;
- Written confirmation that the facility meets the selection criteria in section II.A, including agreement to items 3a–c;
- Written confirmation that the facility can handle a visit of up to 10 FDA staff and contractors; and
- A brief description of prior experiences undergoing an assessment related to the maturity of the facility’s quality culture, including the name of the organization that conducted the assessment and date of the assessment.


Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.

[FR Doc. 2020–22976 Filed 10–15–20; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2018–N–0073]

Agency Information Collection Activities; Proposed Collection; Comment Request; Irradiation in the Production, Processing, and Handling of Food

AGENCY: Food and Drug Administration, HHHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, we, or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of our requirements for food irradiation processors.

DATES: Submit either electronic or written comments on the collection of information by December 15, 2020.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before December 15, 2020. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of December 15, 2020. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

- Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–2018–N–0073 for “Agency Information